Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124897048 | 12489704 | 8 | F | 20160825 | 20160622 | 20160906 | EXP | GB-MHRA-EYC 00139392 | GB-SA-2016SA095878 | AVENTIS | 67.00 | YR | E | F | Y | 80.00000 | KG | 20160906 | MD | GB | GB |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 124897048 | 12489704 | 1 | PS | CLEXANE | ENOXAPARIN SODIUM | 1 | Subcutaneous | UNKNOWN?6 WEEK COURSE ENDED AFTER 32 DAYS?START DATE: (4 WEEKS BEFORE ADMISSION) | 2395 | MG | Y | 5SA23 | 20164 | 120 | MG | SOLUTION FOR INJECTION | QD | ||
| 124897048 | 12489704 | 2 | SS | CLEXANE | ENOXAPARIN SODIUM | 1 | Subcutaneous | UNKNOWN?6 WEEK COURSE ENDED AFTER 32 DAYS?START DATE: (4 WEEKS BEFORE ADMISSION) | 2395 | MG | Y | 5SA74 | 20164 | 120 | MG | SOLUTION FOR INJECTION | QD | ||
| 124897048 | 12489704 | 3 | SS | CLEXANE | ENOXAPARIN SODIUM | 1 | Subcutaneous | UNKNOWN?6 WEEK COURSE ENDED AFTER 32 DAYS?START DATE: (4 WEEKS BEFORE ADMISSION) | 2395 | MG | Y | 5SF52 | 20164 | 120 | MG | SOLUTION FOR INJECTION | QD | ||
| 124897048 | 12489704 | 4 | SS | CLEXANE | ENOXAPARIN SODIUM | 1 | Subcutaneous | UNKNOWN?6 WEEK COURSE ENDED AFTER 32 DAYS?START DATE: (4 WEEKS BEFORE ADMISSION) | 2395 | MG | Y | 5SL64 | 20164 | 120 | MG | SOLUTION FOR INJECTION | QD | ||
| 124897048 | 12489704 | 5 | SS | CLEXANE | ENOXAPARIN SODIUM | 1 | Subcutaneous | UNKNOWN?6 WEEK COURSE ENDED AFTER 32 DAYS?START DATE: (4 WEEKS BEFORE ADMISSION) | 2395 | MG | Y | 5SK16 | 20164 | 120 | MG | SOLUTION FOR INJECTION | QD | ||
| 124897048 | 12489704 | 6 | SS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | Unknown | U | UNKNOWN | 0 | |||||||||
| 124897048 | 12489704 | 7 | C | ADCAL-D3 | CALCIUM CARBONATECHOLECALCIFEROL | 1 | Unknown | 0 | 1 | DF | QD | ||||||||
| 124897048 | 12489704 | 8 | C | DENOSUMAB | DENOSUMAB | 1 | Unknown | EVERY 6 WEEKS | 0 | 1 | DF | INJECTION | |||||||
| 124897048 | 12489704 | 9 | C | HERCEPTIN | TRASTUZUMAB | 1 | Unknown | 0 | 1 | DF | Q3W | ||||||||
| 124897048 | 12489704 | 10 | C | LETROZOLE. | LETROZOLE | 1 | Unknown | 0 | 2.5 | MG | QD | ||||||||
| 124897048 | 12489704 | 11 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Unknown | 0 | 28 | MG | QD | ||||||||
| 124897048 | 12489704 | 12 | C | ZOMORPH | MORPHINE SULFATE | 1 | Unknown | 0 | |||||||||||
| 124897048 | 12489704 | 13 | C | PERJETA | PERTUZUMAB | 1 | Unknown | 0 | 1 | DF | Q3W | ||||||||
| 124897048 | 12489704 | 14 | C | DOCETAXEL. | DOCETAXEL | 1 | Unknown | 0 | |||||||||||
| 124897048 | 12489704 | 15 | C | PERTUZUMAB | PERTUZUMAB | 1 | Unknown | 0 | 1 | DF | Q3W |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 124897048 | 12489704 | 1 | Deep vein thrombosis |
| 124897048 | 12489704 | 2 | Deep vein thrombosis |
| 124897048 | 12489704 | 3 | Deep vein thrombosis |
| 124897048 | 12489704 | 4 | Deep vein thrombosis |
| 124897048 | 12489704 | 5 | Deep vein thrombosis |
| 124897048 | 12489704 | 6 | Antibiotic therapy |
| 124897048 | 12489704 | 7 | Bone disorder |
| 124897048 | 12489704 | 8 | Bone disorder |
| 124897048 | 12489704 | 9 | Breast cancer stage IV |
| 124897048 | 12489704 | 10 | Breast cancer |
| 124897048 | 12489704 | 11 | Gastric disorder |
| 124897048 | 12489704 | 13 | Breast cancer stage IV |
| 124897048 | 12489704 | 14 | Breast cancer stage IV |
| 124897048 | 12489704 | 15 | Breast cancer stage IV |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 124897048 | 12489704 | LT |
| 124897048 | 12489704 | HO |
| 124897048 | 12489704 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 124897048 | 12489704 | Blister | |
| 124897048 | 12489704 | Burning sensation | |
| 124897048 | 12489704 | Dermatitis | |
| 124897048 | 12489704 | Erythema multiforme | |
| 124897048 | 12489704 | Pain | |
| 124897048 | 12489704 | Protein deficiency | |
| 124897048 | 12489704 | Rash erythematous | |
| 124897048 | 12489704 | Scab | |
| 124897048 | 12489704 | Skin erosion | |
| 124897048 | 12489704 | Skin haemorrhage | |
| 124897048 | 12489704 | Stevens-Johnson syndrome | |
| 124897048 | 12489704 | Tachycardia |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 124897048 | 12489704 | 1 | 20160317 | 20160417 | 0 | |
| 124897048 | 12489704 | 2 | 20160317 | 20160417 | 0 | |
| 124897048 | 12489704 | 3 | 20160317 | 20160417 | 0 | |
| 124897048 | 12489704 | 4 | 20160317 | 20160417 | 0 | |
| 124897048 | 12489704 | 5 | 20160317 | 20160417 | 0 | |
| 124897048 | 12489704 | 7 | 20151016 | 0 | ||
| 124897048 | 12489704 | 10 | 20151006 | 0 | ||
| 124897048 | 12489704 | 11 | 20151006 | 0 | ||
| 124897048 | 12489704 | 14 | 20160210 | 0 |